FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:930-932 March 3, 2005 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Horstmann, E. PubMed Citation

Cancer is the most common cause of death in the United States, with more than 500,000 people succumbing each year.¹ Despite dramatic advances in the treatment of certain cancers, the vast majority of patients with metastases die from the cancer. These sobering facts have evoked an intensive and increasingly successful endeavor to unravel the mechanisms that drive the growth of cancer cells, an enterprise that has produced a large number of new drugs, especially agents aimed at particular molecules.

Investigations of anticancer drugs follow a characteristic path: in vitro experiments are followed by studies in animals, and then there is . . . [Full Text of this Article]

Source Information

From the Phase I Program (R.K.) and the Department of Sarcoma Medical Oncology (R.S.B.), Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston.

Related Letters:

Phase 1 Clinical Trials in Oncology
Rothschild B. B., King N. M.P., Muggia F. M., Sekine I., Tamura T., Miller M. J., Horstmann E., Emanuel E. J., Grady C., Kurzrock R., Benjamin R. S.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:2451-2453, Jun 9, 2005. Correspondence

This article has been cited by other articles:

• Graham, J., Hu, J. (2007). The Risk-Benefit Balance In The United States: Who Decides?. Health Aff (Millwood) 26: 625-635 [Abstract] [Full Text]  
• Sharma, S. (2006). Phase I Trials May Not Need to Be Viewed As Extraordinarily Different From Other Clinical Research. JCO 24: e47-e47 [Full Text]  
• Joffe, S., Miller, F. G. (2006). Rethinking Risk-Benefit Assessment for Phase I Cancer Trials. JCO 24: 2987-2990 [Full Text]  
• Rosa, D. D., Harris, J., Jayson, G. C. (2006). The Best Guess Approach to Phase I Trial Design. JCO 24: 206-208 [Full Text]  
• Rothschild, B. B., King, N. M.P., Muggia, F. M., Sekine, I., Tamura, T., Miller, M. J., Horstmann, E., Emanuel, E. J., Grady, C., Kurzrock, R., Benjamin, R. S. (2005). Phase 1 Clinical Trials in Oncology. NEJM 352: 2451-2453 [Full Text]